Humacyte, INC Form 4 insider transactions

Humacyte, Inc. Director Michael T. Constantino was granted 80,000 stock options with an exercise price of $2.41, vesting over four years.

Humacyte, Inc. Director John Philip Bamforth was granted 80,000 stock options with an exercise price of $2.41, vesting over four years.

Humacyte, Inc. Director Diane Seimetz was granted 80,000 stock options with an exercise price of $2.41, vesting over four years.

Humacyte, Inc. Director Kathleen Sebelius was granted 80,000 stock options with an exercise price of $2.41, aligning her interests with shareholder value.

William John Scheessele, Chief Commercial Officer of Humacyte, Inc., reports the acquisition of 6,493 shares of common stock at a price of $1.54 per share on April 14, 2025.

Humacyte's CFO, Dale A. Sander, reports the acquisition of 20,000 shares of common stock at $1.53 per share.

Humacyte's Chief Medical Officer, Shamik J. Parikh, reports purchasing 7,500 shares of common stock at $1.55 per share on April 10, 2025.

Director Kathleen Sebelius reports purchasing 50,000 shares of Humacyte, Inc. common stock at $1.32 per share on April 8, 2025.

Director Charles Bruce Green of Humacyte, Inc. [HUMA] purchased 6,000 shares of common stock at an average price of $1.29 on April 8, 2025.

Director Michael T. Constantino increased his holdings in Humacyte, Inc. by purchasing 16,000 shares of common stock at an average price of $1.26 on April 7, 2025.

Heather Ledbetter Prichard, Chief Operating Officer of Humacyte, Inc., acquired stock options on January 21, 2025.

William John Scheessele, Chief Commercial Officer of Humacyte, Inc., acquired stock options exercisable for 283,101 shares of common stock on January 21, 2025.

Yang Cao, Chief Regulatory Officer of Humacyte, Inc., was granted stock options for 283,101 shares on January 21, 2025.

Brady W. Dougan, a director of Humacyte, Inc., acquired stock options indirectly through a spouse.

Humacyte's CEO, Laura Niklason, reports the acquisition of 1,130,311 stock options exercisable over a period of four years, starting January 21, 2026.

Humacyte's CFO, Dale A. Sander, reports the acquisition of stock options exercisable for 283,101 shares of common stock.

Chief Medical Officer Shamik J. Parikh of Humacyte, Inc. reports the acquisition of stock options.

Humacyte CEO Laura Niklason exercised stock options following the FDA approval of the company's acellular tissue engineered vessel product.

Humacyte's CFO, Dale A. Sander, exercised stock options following the FDA approval of the company's acellular tissue engineered vessel product.

Humacyte's Chief Operating Officer, Heather Ledbetter Prichard, exercised stock options after the company received FDA approval for its acellular tissue engineered vessel product.

Humacyte director Brady W. Dougan exercised stock options following FDA approval of the company's acellular tissue engineered vessel product.

Director Michael T. Constantino of Humacyte, Inc. purchased 4,600 shares of common stock at a price of $4.3872 per share on December 4, 2024.

Humacyte CEO Laura Niklason purchased 1,797 shares of common stock and repaid $8,778.23 in profits related to a previous transaction.

A spouse of a Humacyte director purchased 1,797 shares of common stock, triggering a matchable transaction under Section 16(b) of the Securities Exchange Act of 1934.

Humacyte CEO Laura Niklason indirectly sold shares through Ayabudge LLC, an entity controlled by Brady W. Dougan, to pay down leverage and provide a mechanism for investors to acquire shares.

Humacyte director Brady W. Dougan sold a significant number of shares through his controlled entity, Ayabudge LLC, to pay down leverage.

Charles Bruce Green, a director of Humacyte, Inc., exercised stock options and disposed of 1,200 shares of common stock on September 13, 2024.

Kathleen Sebelius, a director at Humacyte, Inc., reported the acquisition and disposal of common stock and stock options on September 10, 2024.

Brady W. Dougan, a director at Humacyte, Inc., sold shares of common stock through Ayabudge LLC to pay down leverage and provide investors an opportunity to acquire shares.

Humacyte's CEO, Laura Niklason, indirectly sold shares through Ayabudge LLC, an entity controlled by Brady W. Dougan, to pay down leverage and facilitate investor acquisition.